Disease-modifying immunotherapy for the management of autoimmune diabetes
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting β-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against β-cells in thera...
Guardado en:
| Publicado: |
2010
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10217401_v17_n3_p173_Castro http://hdl.handle.net/20.500.12110/paper_10217401_v17_n3_p173_Castro |
| Aporte de: |
| id |
paper:paper_10217401_v17_n3_p173_Castro |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_10217401_v17_n3_p173_Castro2023-06-08T16:00:01Z Disease-modifying immunotherapy for the management of autoimmune diabetes Dendritic cells Immunoregulation Type 1 diabetes autoimmune disease autoimmunity cell activity cell clone cell cloning cell destruction cell disruption conference paper dendritic cell disease course human immunomodulation immunoregulation immunotherapy inner cell mass insulin dependent diabetes mellitus lymphocyte preservation nonhuman pancreas islet beta cell priority journal regulatory T lymphocyte T lymphocyte Animals Antirheumatic Agents Autoimmunity Dendritic Cells Diabetes Mellitus, Type 1 Disease Models, Animal Humans Immunomodulation Immunotherapy Insulin-Secreting Cells T-Lymphocytes, Helper-Inducer Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting β-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against β-cells in therapies for T1D is mandatory to preserve the β-cell mass. Therefore, immunomodulatory strategies directed to inhibiting the activity of self-reactive T cell clones as well as induction of regulatory T cells would be beneficial for prevention of T1D or recurrence of β-cell autoimmunity against islet cell allografts. © 2010 S. Karger AG, Basel. 2010 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10217401_v17_n3_p173_Castro http://hdl.handle.net/20.500.12110/paper_10217401_v17_n3_p173_Castro |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Dendritic cells Immunoregulation Type 1 diabetes autoimmune disease autoimmunity cell activity cell clone cell cloning cell destruction cell disruption conference paper dendritic cell disease course human immunomodulation immunoregulation immunotherapy inner cell mass insulin dependent diabetes mellitus lymphocyte preservation nonhuman pancreas islet beta cell priority journal regulatory T lymphocyte T lymphocyte Animals Antirheumatic Agents Autoimmunity Dendritic Cells Diabetes Mellitus, Type 1 Disease Models, Animal Humans Immunomodulation Immunotherapy Insulin-Secreting Cells T-Lymphocytes, Helper-Inducer |
| spellingShingle |
Dendritic cells Immunoregulation Type 1 diabetes autoimmune disease autoimmunity cell activity cell clone cell cloning cell destruction cell disruption conference paper dendritic cell disease course human immunomodulation immunoregulation immunotherapy inner cell mass insulin dependent diabetes mellitus lymphocyte preservation nonhuman pancreas islet beta cell priority journal regulatory T lymphocyte T lymphocyte Animals Antirheumatic Agents Autoimmunity Dendritic Cells Diabetes Mellitus, Type 1 Disease Models, Animal Humans Immunomodulation Immunotherapy Insulin-Secreting Cells T-Lymphocytes, Helper-Inducer Disease-modifying immunotherapy for the management of autoimmune diabetes |
| topic_facet |
Dendritic cells Immunoregulation Type 1 diabetes autoimmune disease autoimmunity cell activity cell clone cell cloning cell destruction cell disruption conference paper dendritic cell disease course human immunomodulation immunoregulation immunotherapy inner cell mass insulin dependent diabetes mellitus lymphocyte preservation nonhuman pancreas islet beta cell priority journal regulatory T lymphocyte T lymphocyte Animals Antirheumatic Agents Autoimmunity Dendritic Cells Diabetes Mellitus, Type 1 Disease Models, Animal Humans Immunomodulation Immunotherapy Insulin-Secreting Cells T-Lymphocytes, Helper-Inducer |
| description |
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting β-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against β-cells in therapies for T1D is mandatory to preserve the β-cell mass. Therefore, immunomodulatory strategies directed to inhibiting the activity of self-reactive T cell clones as well as induction of regulatory T cells would be beneficial for prevention of T1D or recurrence of β-cell autoimmunity against islet cell allografts. © 2010 S. Karger AG, Basel. |
| title |
Disease-modifying immunotherapy for the management of autoimmune diabetes |
| title_short |
Disease-modifying immunotherapy for the management of autoimmune diabetes |
| title_full |
Disease-modifying immunotherapy for the management of autoimmune diabetes |
| title_fullStr |
Disease-modifying immunotherapy for the management of autoimmune diabetes |
| title_full_unstemmed |
Disease-modifying immunotherapy for the management of autoimmune diabetes |
| title_sort |
disease-modifying immunotherapy for the management of autoimmune diabetes |
| publishDate |
2010 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10217401_v17_n3_p173_Castro http://hdl.handle.net/20.500.12110/paper_10217401_v17_n3_p173_Castro |
| _version_ |
1768544649750773760 |